Anniina Snellman
Docent
aepakk@utu.fi +358 0 231 3872 Kiinamyllynkatu 4-8 Turku |
2 of 3
- Neuropsykologiset tehtäväsarjat Alzheimerin taudin prekliinisen vaiheen hienoisen kognitiivisen heikentymisen havaitsemisessa (2022)
- Duodecim
- N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases (2022)
- Brain
- Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative (2021)
- Alzheimer's Research and Therapy
- Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy (2021)
- Neurology
- Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration (2021)
- Alzheimer's & dementia: diagnosis, assessment & disease monitoring
- Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease (2021)
- JAMA Neurology
- Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals (2021)
- Brain Communications
- Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study (2021)
- Theranostics
- P-tau235: a novel biomarker for staging preclinical Alzheimer's disease (2021)
- Embo molecular medicine
- (S)-[18F]THK5117 brain uptake is associated with Aβ plaques and MAO-B enzyme in a mouse model of Alzheimer's disease (2021)
- Neuropharmacology
- Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum (2021)
- Brain
- Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease (2021)
- Journal of Internal Medicine
- Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative (2020)
- Molecular Psychiatry
- Effect of genotype and age on cerebral [F-18]FDG uptake varies between transgenic APP(swe)-PS1(dE9) and Tg2576 mouse models of Alzheimer's disease (2019)
- Scientific Reports
- Chemical exchange saturation transfer MRI shows low cerebral 2-deoxy-D-glucose uptake in a model of Alzheimer's Disease (2018)
- Scientific Reports
- [F-18]FMPEP-d(2) PET imaging shows age- and genotype-dependent impairments in the availability of cannabinoid receptor 1 in a mouse model of Alzheimer's disease (2018)
- Neurobiology of Aging
- Long-Term Monoacylglycerol Lipase Inhibitor Treatment Decelerates Pathological Changes in APP/PS1-21 Mice, but Behavioral Improvements Require Early-Stage Treatment Onset—Short Report (2018)
- World Journal of Neuroscience
- Neuroinflammation appears early and then plateaus in a mouse model of Alzheimer's disease shown by PET imaging (2018)
- Journal of Nuclear Medicine
- Applicability of [C-11]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model (2017)
- Neurobiology of Aging
- Imaging Alzheimer’s Disease Beta-amyloid Pathology in Transgenic Mouse Models Using Positron Emission Tomography (2017) Snellman Anniina
UTU Research Portal